Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression.
Liu TH, Chen SC, Rau KM, Lu LC, Lin PT, Su YY, Teng W, Lai SW, Yeh RH, Kao TM, Lee PC, Wu CJ, Chen CH, Hsu CH, Lin SM, Huang YH, Chen LT, Cheng AL, Shen YC; Taiwan Liver Cancer Association Research Group (TRG). Liu TH, et al. Among authors: rau km. Liver Cancer. 2024 Feb 1;13(5):509-521. doi: 10.1159/000536549. eCollection 2024 Oct. Liver Cancer. 2024. PMID: 39435270 Free PMC article.
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B; TROPION-Breast01 Investigators. Bardia A, et al. J Clin Oncol. 2025 Jan 20;43(3):285-296. doi: 10.1200/JCO.24.00920. Epub 2024 Sep 12. J Clin Oncol. 2025. PMID: 39265124 Clinical Trial.
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.
Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL. Shen YC, et al. Among authors: rau km. J Clin Oncol. 2024 Dec;42(34):4060-4070. doi: 10.1200/JCO.24.00645. Epub 2024 Aug 28. J Clin Oncol. 2024. PMID: 39197119 Free PMC article.
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial.
Chen TW, Dai MS, Tseng LM, Chen SC, Chao TY, Chao TC, Chang YC, Chiu CF, Liu CT, Lin CH, Liu CY, Chen YF, Chang DY, Yu JC, Rau KM, Hsieh YY, Shen SC, Huang SM, Cheng AL, Lu YS. Chen TW, et al. Among authors: rau km. JAMA Oncol. 2024 Mar 1;10(3):325-334. doi: 10.1001/jamaoncol.2023.5456. JAMA Oncol. 2024. PMID: 38127335 Free PMC article. Clinical Trial.
Comment on: Abdominal Emergencies in Cancer Patients.
Chiu SF, Rau KM, Chen CC, Chiu CC. Chiu SF, et al. Among authors: rau km. Can Assoc Radiol J. 2024 May;75(2):435-436. doi: 10.1177/08465371231211280. Epub 2023 Nov 20. Can Assoc Radiol J. 2024. PMID: 37982318 No abstract available.
118 results